| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| P654601-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $751.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | PC945, a potent, long-acting antifungal triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus . PC945 is also a potent, tightly binding inhibitor of A. fumigatus sterol 14α-demethylase activity, CYP51A and CYP51B , with IC 50 s of 0.23 μM and 0.22 μM, respectively In Vitro PC945 is a triazole antifungal designed for administration via inhalation. PC945 exhibits the most potent antifungal activity on azole-susceptible strain NCPF2010 with the MIC value of 0.063 µg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PC945 (0.56-14 μg/mouse; intranasal; daily for 7 days) substantially inhibits the incidence of rolling behavior . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Specific-pathogen-free A/J mice (male, 5 weeks old, pulmonary Aspergillus infection) Dosage: 0.56, 2.8, 14 μg/mouse (intranasal application of 0.016-, 0.08-, and 0.4-mg/ml suspensions, respectively) Administration: Intranasal; daily for 7 days Result: Substantially inhibited the incidence of rolling behavior. IC50& Target:fungal CYP51A 0.23 μM (IC 50 ) CYP51B 0.22 μM (IC 50 ) |
| Canonical SMILES | CC1=C(C=CC(=C1)N2CCN(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)F)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F |
|---|---|
| Molecular Weight | 682.73 |
Enter Lot Number to search for COA:
